Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

Market Cap	3.44B
Revenue (ttm)	415.14M
Net Income (ttm)	-72.77M
Shares Out	126.54M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	0.25 (0.93%)
Ex-Dividend Date	May 23, 2024

Volume	2,975,400
Average Volume	4,405,860
Open	26.50
Previous Close	26.19
Day's Range	25.90 - 27.10
52-Week Range	23.20 - 48.03
Beta	-0.87
RSI	46.87
Earnings Date	Apr 26, 2025

About SHE:301089

Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research, development, production, and sale of chemical synthesis, biological fermentation nucleoside (acid) APIs, and pharmaceutical intermediates in China and internationally. It offers purine base, pyrimidine base, nucleosides, nucleotide, deoxynucleosides, dehyfrated nucleoside, 2'-modified, Cybinucleoside, and sugar series, and Azvudine intermediate. The company also provides Disodium 5'-cytidylate, Disodium 5'-uridylate, 5'-Adenosine monophosphate, and D-ribose, as well as citicoline sod...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,550
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301089

Financial Performance

In 2023, SHE:301089's revenue was 835.51 million, an increase of 6.47% compared to the previous year's 784.72 million. Earnings were 243.07 million, a decrease of -15.17%.